Floatz logo

Cabozantinib

Nonpapillary Renal Cell Carcinoma

SWOG Cancer Research NetworkSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
73/ 100

Competitive context

111 Active assets in the Nonpapillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
Pazopanib
Academic and Community Cancer Research United
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Cabozantinib is also rated in:

castration-resistant prostate carcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
renal carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
kidney cancerActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →